Alfa Cytology

06/10/2026

Most preclinical Tumor-Infiltrating Lymphocyte (TIL) programs fail for one reason: 𝐧𝐨𝐭 𝐞𝐧𝐨𝐮𝐠𝐡 𝐭𝐢𝐬𝐬𝐮𝐞, 𝐧𝐨𝐭 𝐞𝐧𝐨𝐮𝐠𝐡 𝐭𝐢𝐦𝐞. If your TIL workflow requires a large resected tumor and 3 to 5 weeks of culture time, it was adapted from clinical manufacturing and was not built for preclinical research.

𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲'𝐬 𝑨𝒍𝒇𝒂-𝑻𝑰𝑳™ 𝐋𝐨𝐰-𝐈𝐧𝐩𝐮𝐭 & 𝐑𝐚𝐩𝐢𝐝 𝐓𝐈𝐋 𝐈𝐬𝐨𝐥𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐚𝐝𝐝𝐫𝐞𝐬𝐬𝐞𝐬 𝐭𝐡𝐞 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐜𝐨𝐧𝐬𝐭𝐫𝐚𝐢𝐧𝐭𝐬 𝐨𝐟 𝐞𝐚𝐫𝐥𝐲-𝐬𝐭𝐚𝐠𝐞 𝐢𝐦𝐦𝐮𝐧𝐨-𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡:
• Functional TILs from minimal starting material: small biopsies, patient-derived xenograft (PDX), xenografts, and murine tumor models all supported.
• 10-14 day expansion timeline vs. 3-5 weeks with conventional methods.
• Standardized, preclinical-optimized protocols.
• High-viability output immediately compatible with 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 functional assays, single-cell multi-omics, and 𝘪𝘯 𝘷𝘪𝘷𝘰 efficacy studies.
• Enables pre- and post-treatment biopsy pair analysis for translational insights.

Whether you are screening novel immuno-oncology agents, evaluating combination therapies, profiling the tumor immune microenvironment, or working in complex model systems where tissue availability is constrained, 𝘈𝘭𝘧𝘢-𝘛𝘐𝘓™ pushes your science forward.

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞: https://www.alfacytology.com/til/low-input-rapid-til-isolation-and-expansion.html

05/26/2026

As of today, 15 bispecific antibodies (bsAbs) have received FDA approval, the majority of which are T-cell engagers (TCEs) developed primarily for oncology indications. In addition, more than 600 bsAb therapies are currently being evaluated in clinical trials worldwide, spanning oncology, autoimmune, and neurological diseases. Together, these figures highlight the rapid expansion of this emerging therapeutic modality.

Consistent with this momentum, the bispecific antibody market is growing rapidly, with 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐌𝐚𝐫𝐤𝐞𝐭𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐢𝐧𝐠 𝐚𝐧 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐟𝐫𝐨𝐦 $𝟏𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟒 𝐭𝐨 $𝟓𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟎, reflecting strong clinical and commercial interest in this next-generation antibody class.

Building on this rapid progress in the bsAb field, Alfa Cytology provides an integrated solution designed to translate scientific momentum into functional therapeutic innovation.

Through its innovative 𝐩𝐫𝐨𝐁𝐬𝐀𝐛™ 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦, 𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲 𝐩𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐞𝐧𝐝-𝐭𝐨-𝐞𝐧𝐝 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐝𝐞𝐬𝐢𝐠𝐧 𝐚𝐧𝐝 𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬, enabling simultaneous pathway blockade, immune-cell engagement, and dual-signal modulation within a single molecule.

Uniquely advantages of the proBsAbTM Platform:
• 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐚𝐥 𝐝𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲: over 30 optimized scaffold types for flexible molecular engineering.
• 𝐀𝐈-𝐠𝐮𝐢𝐝𝐞𝐝 𝐝𝐞𝐬𝐢𝐠𝐧 𝐬𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧: predictive modeling of antigen spacing, rotation angles, and immune-synapse topology.
• 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐬𝐬𝐮𝐫𝐚𝐧𝐜𝐞: early elimination of instability risks ensures efficient scale-up.
• 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧-𝐫𝐞𝐚𝐝𝐲 𝐚𝐫𝐜𝐡𝐢𝐭𝐞𝐜𝐭𝐮𝐫𝐞: CHO-optimized expression with validated purification routes.

The proBsAb™ Platform covers a broad range of structural formats, from compact fragment-based constructs to more complex IgG-like architectures.

This is supported by a streamlined development workflow that moves efficiently from target selection through design, expression, functional testing, developability assessment, and final optimization.

Together, this approach enables more precise control over antibody geometry, valency, and manufacturability, supporting the development of next-generation bispecific therapeutics.
𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐡𝐞𝐫𝐞: https://www.alfacytology.com/probsab/

05/21/2026

Many humanized mouse models are designed to capture rapid immune responses, but not all are optimized for long-term immune system development.

𝐔𝐧𝐥𝐢𝐤𝐞 𝐏𝐁𝐌𝐂-𝐛𝐚𝐬𝐞𝐝 𝐦𝐨𝐝𝐞𝐥𝐬, which are typically used for shorter-term studies driven mainly by mature human immune cells, 𝐇𝐒𝐂-𝐡𝐮𝐦𝐚𝐧𝐢𝐳𝐞𝐝 𝐦𝐨𝐝𝐞𝐥𝐬 𝐚𝐫𝐞 𝐞𝐬𝐭𝐚𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐞𝐧𝐠𝐫𝐚𝐟𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐡𝐮𝐦𝐚𝐧 𝐂𝐃𝟑𝟒+ 𝐡𝐞𝐦𝐚𝐭𝐨𝐩𝐨𝐢𝐞𝐭𝐢𝐜 𝐬𝐭𝐞𝐦 𝐜𝐞𝐥𝐥𝐬 𝐭𝐡𝐚𝐭 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐨𝐮𝐬𝐥𝐲 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐞 𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐢𝐦𝐦𝐮𝐧𝐞 𝐜𝐞𝐥𝐥 𝐥𝐢𝐧𝐞𝐚𝐠𝐞𝐬 𝐨𝐯𝐞𝐫 𝐭𝐢𝐦𝐞. This enables more durable and physiologically relevant human immune system reconstitution in vivo.

𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲’𝐬 𝐇𝐮-𝐈𝐦𝐦𝐮𝐧𝐞™ 𝐇𝐒𝐂 𝐌𝐨𝐝𝐞𝐥𝐬 𝐬𝐮𝐩𝐩𝐨𝐫𝐭:
• Long-term immunotherapy efficacy studies
• Immune mechanism and combination therapy research
• Autoimmune disease modeling
• Infectious disease and vaccine development

With sustained generation of T cells, B cells, NK cells, and myeloid cells, Hu-Immune™ HSC Models provide a robust platform for studying complex human immune interactions in preclinical research.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐭𝐨 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐦𝐨𝐫𝐞 𝐚𝐧𝐝 𝐥𝐞𝐚𝐫𝐧 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐩𝐫𝐞𝐯𝐢𝐨𝐮𝐬 𝐜𝐚𝐬𝐞 𝐬𝐭𝐮𝐝𝐢𝐞𝐬: https://www.hu-immune.com/huhsc-humanized-model.html

05/15/2026

𝐌𝐚𝐧𝐲 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐬𝐡𝐨𝐰 𝐬𝐭𝐫𝐨𝐧𝐠 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐢𝐧 𝐭𝐫𝐚𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐚𝐧𝐢𝐦𝐚𝐥 𝐦𝐨𝐝𝐞𝐥𝐬 𝐛𝐮𝐭 𝐟𝐚𝐢𝐥 𝐢𝐧 𝐡𝐮𝐦𝐚𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 because conventional models cannot fully reproduce the complexity of the human immune system. This makes it challenging to accurately evaluate how human immune cells respond to new therapies before clinical testing.

𝐏𝐞𝐫𝐢𝐩𝐡𝐞𝐫𝐚𝐥 𝐁𝐥𝐨𝐨𝐝 𝐌𝐨𝐧𝐨𝐧𝐮𝐜𝐥𝐞𝐚𝐫 𝐂𝐞𝐥𝐥𝐬 (𝐏𝐁𝐌𝐂𝐬) are immune cells isolated from human blood, including T cells, B cells, NK cells, and monocytes. These cells play central roles in immune response, inflammation, and cancer immunity, making PBMC-based humanized mouse models valuable tools for translational immunology research.

𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲’𝐬 𝐇𝐮-𝐈𝐦𝐦𝐮𝐧𝐞™ 𝐏𝐁𝐌𝐂 𝐌𝐨𝐝𝐞𝐥𝐬 provide a diverse portfolio of humanized mouse systems tailored to different immunology and oncology research applications, including:
• 𝐡𝐮𝐏𝐁𝐌𝐂-𝐌𝐨𝐧𝐨 𝐌𝐢𝐜𝐞 for macrophage-targeting drugs (e.g., CD47 antibodies), cancer vaccine evaluation, tumor microenvironment research.
• 𝐡𝐮𝐏𝐁𝐌𝐂-𝐓 𝐌𝐢𝐜𝐞 for CAR-T/TCR-T cell therapy evaluation, immune checkpoint inhibitor (e.g., PD-1/PD-L1) efficacy, bispecific antibody assessment.
• 𝐡𝐮𝐏𝐁𝐌𝐂-𝐍𝐊/𝐁 𝐌𝐢𝐜𝐞 for NK cell therapy, antibody-dependent cell-mediated cytotoxicity (ADCC) studies, B cell-targeting drug evaluation.
• 𝐡𝐮𝐏𝐁𝐌𝐂-𝐌𝐇𝐂 𝐊𝐎 𝐌𝐢𝐜𝐞 for long-term efficacy studies, combination therapy evaluation, exploratory research requiring wider observation windows.

𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲’𝐬 𝐇𝐮-𝐈𝐦𝐦𝐮𝐧𝐞™ 𝐏𝐁𝐌𝐂 𝐌𝐨𝐝𝐞𝐥𝐬 𝐚𝐧𝐝 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞 𝐲𝐨𝐮𝐫 𝐭𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡:
https://www.hu-immune.com/hupbmc-humanized-model.html

05/12/2026

𝐌𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝟗𝟎% 𝐨𝐟 𝐝𝐫𝐮𝐠 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞𝐬 𝐭𝐡𝐚𝐭 𝐬𝐡𝐨𝐰 𝐩𝐫𝐨𝐦𝐢𝐬𝐞 𝐢𝐧 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 𝐮𝐥𝐭𝐢𝐦𝐚𝐭𝐞𝐥𝐲 𝐟𝐚𝐢𝐥 𝐢𝐧 𝐡𝐮𝐦𝐚𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬, often because conventional animal models cannot fully reproduce human immune biology. Humanized mouse models aim to address this translational gap by enabling the study of human immune responses 𝘪𝘯 𝘷𝘪𝘷𝘰.

𝐎𝐮𝐫 𝑯𝒖-𝑰𝒎𝒎𝒖𝒏𝒆™ 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 provides advanced humanized mouse models, including 𝐡𝐮𝐏𝐁𝐌𝐂 and 𝐂𝐃𝟑𝟒+ 𝐇𝐒𝐂-based systems.

𝐊𝐞𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞:
• Built on validated and widely adopted humanized mouse models.
• Standardized experimental systems combined with flexible, customizable study designs.
• Generation of reproducible, clinically relevant, and filing ready preclinical data.
• Applications across immuno-oncology, inflammation, and autoimmune disease research.

Our integrated workflow provides𝐞𝐧𝐝-𝐭𝐨-𝐞𝐧𝐝 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐟𝐫𝐨𝐦 𝐦𝐨𝐝𝐞𝐥 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝒊𝒏 𝒗𝒊𝒗𝒐 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐬𝐭𝐮𝐝𝐢𝐞𝐬, supported by dedicated scientific partnership throughout model selection and data interpretation.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲’𝐬 𝑯𝒖-𝑰𝒎𝒎𝒖𝒏𝒆™ 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 to accelerate translational research and improve confidence in preclinical immunology studies: https://www.hu-immune.com/platform.html

04/08/2026

Despite the clinical success of PARP inhibitors, challenges such as toxicity, resistance, and limited patient stratification continue to constrain their full therapeutic potential.

𝐀𝐭 𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲, we address these gaps through integrated PARP-focused research solutions - from improving PARP1 selectivity and reducing off-target effects to enabling biomarker discovery and optimizing combination strategies.

Our capabilities are supported by advanced preclinical platforms, including patient-derived xenograft (PDX) models, which closely recapitulate human tumor biology and enable more predictive efficacy evaluation.

As highlighted in the𝐜𝐚𝐬𝐞 𝐬𝐭𝐮𝐝𝐲, our platform enables the establishment of PDX models and evaluation of a selective PARP1 inhibitor (A1), which demonstrated:
• Potent, dose-dependent antitumor activity in PDX models
• Strong efficacy compared to the first-generation PARP1/2 inhibitor olaparib
• Clear PK/PD relationships supporting translational potential

By combining biologically relevant models with PK/PD insights, we help accelerate the development of next-generation PARP therapies while addressing key limitations in the field.

𝐀𝐬 𝐚 𝐛𝐫𝐨𝐚𝐝 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐂𝐑𝐎, 𝐨𝐮𝐫 𝐜𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬 𝐞𝐱𝐭𝐞𝐧𝐝 𝐟𝐚𝐫 𝐛𝐞𝐲𝐨𝐧𝐝 𝐭𝐡𝐢𝐬 𝐜𝐚𝐬𝐞 𝐬𝐭𝐮𝐝𝐲 - 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐡𝐨𝐰 𝐰𝐞 𝐜𝐚𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐲𝐨𝐮𝐫 𝐏𝐀𝐑𝐏 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬: https://www.alfa-parp.com/contact-us.html

03/31/2026

Poly [ADP-ribose] polymerase (PARP) is a family of 17 proteins involved in DNA damage sensing and repair, with PARP1 being the most studied.𝐏𝐀𝐑𝐏 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 (𝐏𝐀𝐑𝐏𝐢) 𝐞𝐱𝐩𝐥𝐨𝐢𝐭 𝐬𝐲𝐧𝐭𝐡𝐞𝐭𝐢𝐜 𝐥𝐞𝐭𝐡𝐚𝐥𝐢𝐭𝐲 𝐢𝐧 𝐭𝐮𝐦𝐨𝐫𝐬 𝐰𝐢𝐭𝐡 𝐁𝐑𝐂𝐀𝟏/𝟐 𝐨𝐫 𝐨𝐭𝐡𝐞𝐫 𝐡𝐨𝐦𝐨𝐥𝐨𝐠𝐨𝐮𝐬 𝐫𝐞𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 (𝐇𝐑) 𝐝𝐞𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐢𝐞𝐬. By blocking PARP activity, single-strand breaks accumulate and convert into double-strand breaks (DSBs) during DNA replication. Normal cells can repair these DSBs, but HR-deficient cancer cells cannot, leading to cell death.

𝐌𝐨𝐬𝐭 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐏𝐀𝐑𝐏𝐢 𝐭𝐚𝐫𝐠𝐞𝐭 𝐛𝐨𝐭𝐡 𝐏𝐀𝐑𝐏𝟏 𝐚𝐧𝐝 𝐏𝐀𝐑𝐏𝟐, 𝐛𝐮𝐭:
• Lack of selectivity can cause off-target toxicity, such as bone marrow suppression, since PARP2 contributes to hematopoiesis. Developing PARP1-selective inhibitors could reduce these side effects while retaining anticancer efficacy.

𝐎𝐭𝐡𝐞𝐫 𝐦𝐚𝐣𝐨𝐫 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞:
• Tumor resistance through HR restoration or drug efflux
• Limited biomarkers to identify responsive patients
• PARP trapping toxicity
• Complications from combination therapies
• Pharmacokinetic variability affecting efficacy and tolerability

Addressing these issues is key to optimizing PARPi therapy.
𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲 𝐩𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐏𝐀𝐑𝐏-𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 to:
• Improve inhibitor selectivity
• Reduce toxicity
• Identify responsive tumors

Our platform supports biomarker discovery, preclinical testing, and combination therapy evaluation, helping address resistance and optimize PARP-based cancer treatments.

Get in touch with us, and we will guide you through our services in more detail: https://www.alfa-parp.com/contact-us.html

03/20/2026

While Fibroblast Activation Protein (FAP) (Seprase) is mostly studied in tumors, it also plays a major role in other serious conditions. FAP is a protein found on the surface of "activated" fibroblasts - cells that are actively changing the structure of our tissues.

𝐖𝐡𝐞𝐫𝐞 𝐅𝐀𝐏 𝐝𝐫𝐢𝐯𝐞𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧:
• 𝐅𝐢𝐛𝐫𝐨𝐭𝐢𝐜 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬: FAP is a marker for active scarring (fibrosis). It is usually only found in injured or diseased tissues. It helps build up the "extra-cellular matrix" (the scaffolding of our organs), which leads to the hardening of tissue. FAP-targeted drugs are currently being developed for liver, kidney, lung, and heart fibrosis.
• 𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬: In these conditions, the body’s immune system causes fibroblasts to stay "activated". FAP-targeted radioligands are now being tested in preclinical research for Crohn’s disease, IgG4-Related disease, and Rheumatoid arthritis.

𝐂𝐮𝐫𝐫𝐞𝐧𝐭𝐥𝐲:
• 𝐋𝐢𝐦𝐢𝐭𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐟𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧: conventional imaging methods, such as CT and MRI, often fail to detect fibrosis until advanced stages. Biopsies, while informative, are invasive, carry bleeding risks, and sample only a small portion of tissue - potentially missing disease heterogeneity. Standard PET imaging (FDG-based) relies on glucose uptake, but high physiological glucose use in organs like the brain, heart, and gastrointestinal tract creates significant background noise, reducing diagnostic accuracy.
• 𝐇𝐢𝐠𝐡 𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐨𝐟 𝐬𝐲𝐬𝐭𝐞𝐦𝐢𝐜 𝐝𝐫𝐮𝐠𝐬: Current treatments for autoimmune diseases - including corticosteroids and broad immunosuppressants - act systemically, often leading to serious side effects such as increased infection risk, bone loss, and organ toxicity. In contrast, FAP-targeted approaches offer a more precise strategy - given its limited expression in healthy adult tissues and enrichment at sites of active remodeling, FAP represents a promising target for more selective diagnostic and therapeutic approaches.

We provide specialized Therapeutics, Diagnostic Development, and Preclinical Research services to help researchers leverage FAP for high-precision medicine to track and treat these diseases using FAP.

Check out our services and contact us to discuss next steps: https://www.alfa-fap.com/

03/19/2026

𝐖𝐡𝐲 𝐅𝐀𝐏 𝐢𝐬 𝐚 𝐠𝐨𝐨𝐝 𝐮𝐧𝐢𝐯𝐞𝐫𝐬𝐚𝐥 𝐭𝐚𝐫𝐠𝐞𝐭 𝐟𝐨𝐫 𝐜𝐚𝐧𝐜𝐞𝐫?

One of the biggest goals in oncology is finding a universal target - a marker present in many tumors but limited in healthy tissue.

Recent progress in 𝐭𝐡𝐞𝐫𝐚𝐧𝐨𝐬𝐭𝐢𝐜𝐬 (𝐜𝐨𝐦𝐛𝐢𝐧𝐢𝐧𝐠 𝐢𝐦𝐚𝐠𝐢𝐧𝐠 𝐚𝐧𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐲) allows the same targeting molecule to both detect and treat cancer. These molecules can be labeled with different radioactive isotopes depending on the purpose:
𝐅𝐨𝐫 𝐢𝐦𝐚𝐠𝐢𝐧𝐠: Ga-68, F-18
𝐅𝐨𝐫 𝐭𝐡𝐞𝐫𝐚𝐩𝐲: Lu-177, Y-90, Ac-225

𝐖𝐡𝐲 𝐅𝐀𝐏 𝐬𝐭𝐚𝐧𝐝𝐬 𝐨𝐮𝐭?

Many current targets work well but are limited to specific cancers:
• 𝐏𝐒𝐌𝐀: mainly prostate cancer (found in about 95% of cases), but not very useful for other types.
• 𝐒𝐒𝐓𝐑𝟐: The gold standard for neuroendocrine tumors, but rarely seen in broader carcinomas.

A study in Frontiers in Immunology analyzed 𝐨𝐯𝐞𝐫 𝟏,𝟐𝟎𝟎 𝐭𝐮𝐦𝐨𝐫 𝐬𝐚𝐦𝐩𝐥𝐞𝐬 𝐚𝐜𝐫𝐨𝐬𝐬 𝟐𝟑 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐲𝐩𝐞𝐬 𝐚𝐧𝐝 𝐬𝐮𝐛𝐭𝐲𝐩𝐞𝐬 to understand how FAP is expressed in real human cancers - FAP is overexpressed in the stroma of over 90% of all epithelial tumors, including breast, lung, colorectal, and pancreatic cancers: https://doi.org/10.3389/fimmu.2024.1352615
• Broad tumor coverage – present across many cancer types
• High tumor-to-background contrast – enables clearer imaging
• Potential to detect tumors missed by FDG PET

𝐀𝐧𝐨𝐭𝐡𝐞𝐫 𝐫𝐞𝐜𝐞𝐧𝐭 𝐬𝐭𝐮𝐝𝐲 in 14 mucoepidermoid carcinoma patients showed that 𝟔𝟖𝐆𝐚-𝐅𝐀𝐏𝐈 𝐏𝐄𝐓/𝐂𝐓 𝐝𝐞𝐭𝐞𝐜𝐭𝐞𝐝 𝟏𝟎𝟎% 𝐨𝐟 𝐩𝐫𝐢𝐦𝐚𝐫𝐲 𝐭𝐮𝐦𝐨𝐫𝐬 𝐚𝐧𝐝 𝟓𝟐 𝐦𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐥𝐞𝐬𝐢𝐨𝐧𝐬 (33 lymph nodes and 19 distant metastases), 𝐨𝐮𝐭𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝟏𝟖𝐅-𝐅𝐃𝐆 𝐏𝐄𝐓/𝐂𝐓 (detected 85.7% of primary tumors), a current standard-of-care for metabolic tumor imaging. This sets a perfect example of FAP usage in theranostic radiopharmaceuticals.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐡𝐞𝐫𝐞: https://doi.org/10.1038/s41598-025-34528-9

This study evaluated the diagnostic potential of the FAP-targeted tracer ⁶⁸Ga-FAPI PET/CT in mucoepidermoid carcinoma (MEC), demonstrating its superior sensitivity over ¹⁸F-FDG PET/CT in detecting primary tumors (100% vs. 85.7%) and metastatic lesions (33 lymph nodes and 19 distant metastases...

03/11/2026

𝐅𝐢𝐛𝐫𝐨𝐛𝐥𝐚𝐬𝐭 𝐀𝐜𝐭𝐢𝐯𝐚𝐭𝐢𝐨𝐧 𝐏𝐫𝐨𝐭𝐞𝐢𝐧 (𝐒𝐞𝐩𝐫𝐚𝐬𝐞 | 𝐅𝐀𝐏) is a promising therapeutic and diagnostic target, highly overexpressed by cancer-associated fibroblasts (CAF) in the tumor microenvironment.

CAFs are deeply embedded within tumors, making them difficult to target with conventional therapies. Theranostic radiopharmaceuticals provide a precise approach to both visualize and treat these tumor-supporting cells.

𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲 (𝐂𝐑𝐎) provides specialized FAP-targeted drug discovery and preclinical development services, including radiopharmaceutical development.

𝐎𝐮𝐫 𝐜𝐚𝐬𝐞 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞:
• 𝐋𝐚𝐛𝐞𝐥𝐢𝐧𝐠 𝐂𝐨𝐧𝐝𝐢𝐭𝐢𝐨𝐧 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧: We evaluated the uptake of radioactive FAP tracers in stably transfected HT1080-huFAP cells and U-87 MG cells with endogenous FAP expression. Uptake was compared at 37°C and 4°C to assess the impact of temperature on radiolabeling efficiency.
• 𝑰𝒏 𝒗𝒊𝒕𝒓𝒐 𝐅𝐮𝐧𝐜𝐭𝐢𝐨𝐧 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧: The specific binding and functional properties of theranostic radiopharmaceuticals were confirmed by comparing uptake rates in HT1080-huFAP (FAP-high expressing) versus HT1080-WT (FAP-negative) cells, along with time-dependent uptake kinetics in HT1080-huFAP cells.
• 𝑰𝒏 𝒗𝒊𝒗𝒐 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲 & 𝐬𝐚𝐟𝐞𝐭𝐲 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭: The efficacy, safety, and targeted delivery of FAP-targeted theranostic radiopharmaceuticals were evaluated in tumor-bearing mice. Assessments included tumor inhibition (volume), systemic safety (weight changes), and organ-specific distribution (biodistribution imaging and quantification) across different dosages.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐨𝐮𝐫 𝐟𝐫𝐞𝐞 𝐛𝐫𝐨𝐜𝐡𝐮𝐫𝐞 on the discovery and development of novel 𝐭𝐡𝐞𝐫𝐚𝐧𝐨𝐬𝐭𝐢𝐜 𝐫𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 to learn more about our capabilities: https://www.alfa-fap.com/resources.html